Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis
Open accessAbstract
Background and Aims Studies are needed to determine the long-term effects of bariatric surgery for patients with nonalcoholic steatohepatitis (NASH). We evaluated sequential liver samples, collected the time of bariatric surgery and 1 and 5 years later, to assess the long-term effects of bariatric surgery in patients with NASH. Methods We performed a prospective study of 180 severely obese patients with biopsy-proven NASH, defined by the NASH clinical research network histologic scores. The patients underwent bariatric surgery at a single center in France and were followed for 5 years. We obtained liver samples from 125 of 169 patients (76%) having reached 1 year and 64 of 94 patients (68%) having reached 5 years after surgery. The primary endpoint was the resolution of NASH without worsening of fibrosis at 5 years. Secondary end points were improvement in fibrosis (reduction of ≥1 stage) at 5 years and regression of fibrosis and NASH at 1 and 5 years. Results At 5 years after bariatric surgery, NASH was resolved, without worsening fibrosis, in samples from 84% of patients (n = 64; 95% confidence interval, 73.1%-92.2%). Fibrosis decreased, compared with baseline, in samples from 70.2% of patients (95% CI, 56.6%-81.6%). Fibrosis disappeared from samples from 56% of all patients (95% CI, 42.4%-69.3%) and from samples from 45.5% of patients with baseline bridging fibrosis. Persistence of NASH was associated with no decrease in fibrosis and less weight loss (reduction in body mass index of 6.3 ± 4.1 kg/m 2 in patients with persistent NASH vs reduction of 13.4 ± 7.4 kg/m 2 ; P = .017 with resolution of NASH). Resolution of NASH was observed at 1 year after bariatric surgery in biopsies from 84% of patients, with no significant recurrence between 1 and 5 years ( P = .17). Fibrosis began to decrease by 1 year after surgery and continued to decrease until 5 years ( P < .001). Conclusions In a long-term follow-up of patients with NASH who underwent bariatric surgery, we observed resolution of NASH in liver samples from 84% of patients 5 years later. The reduction of fibrosis is progressive, beginning during the first year and continuing through 5 years.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In an observational study, MASH was resolved in 84% of 180 individuals with class 2 obesity and MASH 5 years after Roux-en-Y gastric bypass (66%), sleeve gastrectomy (12%) or gastric banding (22%).
“In an observational study, MASH was resolved in 84% of 180 individuals with class 2 obesity and MASH 5 years after Roux-en-Y gastric bypass (66%), sleeve gastrectomy (12%) or gastric banding (22%).”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [443]
The Cohort Patients section reports 180 participants with biopsy-proven NASH, and the Primary Outcome section reports resolution without worsening fibrosis in 84.4% of the 64 patients assessed at five years. Supplementary Table 1 supports the rounded percentages for bypass, sleeve gastrectomy and banding, but also lists one patient who had a shunt. Table 1 gives a mean baseline BMI of 48.1 kg/m², so describing all 180 as having class 2 obesity is unsupported; the 84% result also applies to the 64 with five-year biopsies, not all 180. (LLM, conf=0.91)
Experimental — accuracy not yet measuredPioglitazone therapy, GLP-1 RA therapy, and metabolic surgery have all been shown to reduce NASH activity; pioglitazone therapy and metabolic surgery may also improve hepatic fibrosis.
“Pioglitazone therapy, GLP-1 RA therapy, and metabolic surgery have all been shown to reduce NASH activity; pioglitazone therapy and metabolic surgery may also improve hepatic fi brosis (188,292 -298).”
Liver fibrosis can be a reversible process under certain conditions, particularly if the underlying cause of injury is removed.
“One of the most promising developments in the field is the growing consensus that liver fibrosis can be a reversible process under certain conditions, particularly if the underlying cause of injury is removed (84–86).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [85]
Procedures such as RYGB and VSG are associated with significant metabolic improvements and reductions in NAFLD severity, including reductions in liver fat, liver enzymes, and fibrosis.
“Procedures like Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) are associated with significant metabolic improvements and reductions in NAFLD severity [13,14,15], including reductions in liver fat, liver enzymes, and fibrosis [16,17,18].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [16]
The reduction of fibrosis after bariatric surgery is progressive, beginning during the first year and continuing through 5 years.
“The reduction of fibrosis is progressive, beginning during the first year and continuing through 5 years [4,127].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [127]
In a long-term follow-up study of patients with MASH who underwent bariatric surgery, resolution of MASH in liver samples was observed in 84% of patients 5 years later.
“In a long-term follow-up study of patients with MASH who underwent bariatric surgery, the resolution of MASH in liver samples was observed from 84% of patients 5 years later.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [127]
Weight loss either through lifestyle intervention or bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) improves the lipid profile by reducing total TAGs, and increasing PC, PE and HDL concentrations.
“Weight loss either through lifestyle intervention68 or bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy)69,70 improves the lipid profile by reducing total TAGs, and increasing PC, PE and HDL concentrations.125”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [70]
MASH fibrosis is reversible in non-cirrhotic liver, but there is no evidence yet that cirrhosis in MASH is reversible.
“Nevertheless, these interventions suggest that, like HCV and HBV, MASH fibrosis is reversible in non-cirrhotic liver, but unlike in HCV and HBV there is no evidence yet that cirrhosis in MASH is reversible (259).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [259]
Liver wound healing is dynamic and reversible, with fibrosis regression seen after effective viral hepatitis treatment and after bariatric surgery in NASH.
“Wound healing in the liver is dynamic and reversible,105 with ample evidence of fibrosis regression after effective treatment of viral hepatitis, and even following bariatric surgery in patients with NASH.106”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · see citing works
Bariatric Surgery: A Systematic Review and Meta-analysis
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004) · JAMA · doi:10.1001/jama.292.14.1724 · Cited by 6,800 · see citing works
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836 · see citing works
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668 · see citing works
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907 · see citing works
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,798 · see citing works
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · see citing works
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934 · see citing works
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572 · see citing works
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492 · see citing works
Long-term weight loss maintenance
Wing, R. R., & Phelan, S. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.1.222s · Cited by 1,941 · see citing works
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Brethauer, S. A., Navaneethan, S. D., Aminian, A., Pothier, C. E., Kim, E. S. H., Nissen, S. E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401329 · Cited by 1,901 · see citing works
Wong, R. J., Aguilar, M. E. F., Cheung, R. C., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,821 · see citing works
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788 · see citing works
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,770 · see citing works
Bariatric Surgery and Long-term Cardiovascular Events
Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C. D., Karason, K., Wedel, H., Ahlin, S., Anveden, Å., Bengtsson, C., Bergmark, G., et al. (2012) · JAMA · doi:10.1001/jama.2011.1914 · Cited by 1,656 · see citing works
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330 · see citing works
Brunt, E. M., Kleiner, D. E., Wilson, L. A., Belt, P., & Neuschwander-Tetri, B. A. (2011) · Hepatology · doi:10.1002/hep.24127 · Cited by 1,251 · see citing works
Sjöström, L., Gummesson, A., Sjöström, C. D., Narbro, K., Peltonen, M., Wedel, H., Bengtsson, C., Bouchard, C., Carlsson, B., Dahlgren, S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70159-7 · Cited by 770 · see citing works
Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients
Lassailly, G., Caiazzo, R., Buob, D., Pigeyre, M., Verkindt, H., Labreuche, J., Raverdy, V., Leteurtre, E., Dharancy, S., Louvet, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.014 · Cited by 762 · see citing works
Self-citationEndpoints and clinical trial design for nonalcoholic steatohepatitis
Sanyal, A. J., Brunt, E. M., Kleiner, D. E., Kowdley, K. V., Chalasani, N., Lavine, J. E., Ratziu, V., & McCullough, A. J. (2011) · Hepatology · doi:10.1002/hep.24376 · Cited by 751 · see citing works
Mathurin, P., Hollebecque, A., Arnalsteen, L., Buob, D., Leteurtre, E., Caiazzo, R. J., Pigeyre, M., Verkindt, H., Dharancy, S., Louvet, A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.052 · Cited by 483 · see citing works
Self-citationMerriman, R. B., Ferrell, L. D., Patti, M. G., Weston, S. R., Pabst, M. S., Aouizerat, B. E., & Bass, N. M. (2006) · Hepatology · doi:10.1002/hep.21346 · Cited by 326 · see citing works
Jejunoileal Bypass for Morbid Obesity
Hocking, M. P., Duerson, M. C., O’Leary, J. P., & Woodward, E. R. (1983) · New England Journal of Medicine · doi:10.1056/nejm198304283081703 · Cited by 227 · see citing works
The Evolution of Severe Steatosis After Bariatric Surgery Is Related to Insulin Resistance
Mathurin, P., Gonzalez, F., Kerdraon, O., Leteurtre, E., Arnalsteen, L., Hollebecque, A., Louvet, A., Dharancy, S., Cocq, P., Jany, T., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.024 · Cited by 157 · see citing works
Self-citationAnty, R., Marjoux, S., Iannelli, A., Patouraux, S., Schneck, A.-S., Bonnafous, S., Gire, C., Amzolini, A. M., Amor, I. B., Saint‐Paul, M., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.014 · Cited by 143 · see citing works
Brunt, E. M., Kleiner, D. E., Behling, C. A., Contos, M. J., Cummings, O. W., Ferrell, L. D., Torbenson, M. S., & Yeh, M. M. (2011) · Hepatology · doi:10.1002/hep.24347 · Cited by 35 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Non-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789 · see citing works
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · see citing works
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · see citing works
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048 · see citing works
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021 · see citing works
Eisenberg, D., Shikora, S. A., Aarts, E., Aminian, A., Angrisani, L., Cohen, R. V., De Luca, M., Faria, S. L., Goodpaster, K. P. S., Haddad, A., et al. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.08.013 · Cited by 985 · see citing works
“[95] Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al.”
BackgroundTirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005 · see citing works
Gut-liver axis: Pathophysiological concepts and clinical implications
Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843 · see citing works
Eslam, M., Sarin, S. K., Wong, V. W., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M., Shiha, G. E.-S., Yilmaz, Y. N., Gani, R. A., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 837 · see citing works
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803 · see citing works
“The most successful antifibrotic therapy is the efficient treatment of the underlying liver disease, as shown by the effectiveness of HCV elimination by modern anti-virals 5 and by the results in two clinical trials of bariatric surgery in 288 and 180 patients with fibrotic NASH 8,195 .”
Contemporary medical, device, and surgical therapies for obesity in adults
Perdomo, C. M., Cohen, R. V., Sumithran, P., Clément, K., & Frühbeck, G. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02403-5 · Cited by 738 · see citing works
Eisenberg, D., Shikora, S. A., Aarts, E., Aminian, A., Angrisani, L., Cohen, R. V., de Luca, M., Faria, S. L., Goodpaster, K. P. S., Haddad, A., et al. (2023) · Obesity Surgery · doi:10.1007/s11695-022-06332-1 · Cited by 710 · see citing works
“early cases, leading to a reduced risk of hepatocellular carcinoma [94, 95].”
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Deprince, A., Haas, J. T., & Staels, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101092 · Cited by 558 · see citing works
“com progressively decrease histological fibrosis in NASH patients [128].”
Background(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 510 · see citing works
Obesity as a multisystem disease: Trends in obesity rates and obesity‐related complications
Sarma, S., Sockalingam, S., & Dash, S. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14290 · Cited by 461 · see citing works
“NASH was more likely to persist in those with least weight loss.(91) It is not established whether intervention earlier in the course of the disease prevents more serious liver disease.”
BackgroundHepatic fibrosis 2022: Unmet needs and a blueprint for the future
Friedman, S. L., & Pinzani, M. (2022) · Hepatology · doi:10.1002/hep.32285 · Cited by 430 · see citing works
“Natural history studies in hepatitis B and C, as well as NASH, suggest that some fibrosis reduction is possible in a year or less but is greater at 5 years.[108,149,150] Moreover, whereas reversal of cirrhosis has been documented in HBV and HCV, this has not been consistently observed in NASH cirrhosis.”
BackgroundStefan, N., Yki‐Järvinen, H., & Neuschwander‐Tetri, B. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00318-8 · Cited by 450 · see citing works
NAFLD: Mechanisms, Treatments, and Biomarkers
Nassir, F. (2022) · Biomolecules · doi:10.3390/biom12060824 · Cited by 422 · see citing works
Aminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.19569 · Cited by 375 · see citing works
Israelsen, M. E., Francque, S., Tsochatzis, E. A., & Krag, A. A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01811-7 · Cited by 370 · see citing works
Verrastro, O., Panunzi, S., Castagneto-Gissey, L., De Gaetano, A., Lembo, E., Capristo, E., Guidone, C., Angelini, G., Pennestrì, F., Sessa, L., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00634-7 · Cited by 362 · see citing works
Liver Transplantation 2023: Status Report, Current and Future Challenges
Terrault, N. A., Francoz, C., Berenguer, M., Charlton, M., & Heimbach, J. K. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.005 · Cited by 323 · see citing works
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321 · see citing works
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki‐Järvinen, H., & Loomba, R. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 336 · see citing works
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hagström, H., Shang, Y., Hegmar, H., & Nasr, P. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00193-6 · Cited by 310 · see citing works
Harrison, S. A., Frias, J. P., Neff, G., Abrams, G. A., Lucas, K. J., Sanchez, W., Gogia, S., Sheikh, M. Y., Behling, C., Bedossa, P., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00272-8 · Cited by 276 · see citing works
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Kang, S. H., Lee, H. W., Yoo, J., Cho, Y., Kim, S. U., Lee, T. H., Jang, B. K., Ahn, S. B., Ahn, S. B., Kim, H., et al. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0178 · Cited by 271 · see citing works
“In a 5-year follow-up study of biopsy-confirmed NASH patients who underwent bariatric surgery, BMI, the amount of fat in the liver, and NAS were all found to be reduced, and histological improvement in the fibrosis stage was noted after surgery.(352) Recent meta-analyses identified that bariatric surgery effectively r…”
BackgroundPeroxisomal β-oxidation acts as a sensor for intracellular fatty acids and regulates lipolysis
Ding, L., Sun, W., Baláž, M., He, A., Klug, M., Wieland, S. F., Caiazzo, R. J., Raverdy, V., Pattou, F. N., Lefèbvre, P., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00489-2 · Cited by 249 · see citing works
Self-citationMetabolic Dysfunction–Associated Steatotic Liver Disease in Adults
Tilg, H., Petta, S., Stefan, N., & Targher, G. (2025) · JAMA · doi:10.1001/jama.2025.19615 · Cited by 281 · see citing works
NAFLD‐related hepatocellular carcinoma: The growing challenge
Shah, P. A., Patil, R., & Harrison, S. A. (2022) · Hepatology · doi:10.1002/hep.32542 · Cited by 232 · see citing works
“[35] The beneficial outcomes with bariatric surgery could be related to the reduction of the inflammatory state, as studies have shown a progressive reduction in hepatic fibrosis and NASH with bariatric surgery.[36] In summary, clinical studies evaluating bariatric surgery suggest its use beyond weight loss strategy i…”
BackgroundAmerican Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s008 · Cited by 236 · see citing works
Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
Grander, C., Grabherr, F., & Tilg, H. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad095 · Cited by 216 · see citing works
“a sign of advanced liver disease), fibrosis disappeared after 5 years in the follow-up biopsy.(160) Together, these data indicate that bariatric surgery could be an appropriate therapeutic option for selected patients with NAFLD.”
Non-alcoholic fatty liver disease: A patient guideline
Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264 · see citing works
“The evidence specifically supporting bariatric surgery in NAFLD is exclusively derived from observational studies.(217) In these studies, liver biopsies were performed during the surgery and during follow-up.”
BackgroundCurrent therapies and new developments in NASH
Dufour, J., Anstee, Q. M., Bugianesi, E., Harrison, S. A., Loomba, R. S., Paradis, V., Tilg, H., Wong, V. W., & Zelber‐Sagi, S. (2022) · Gut · doi:10.1136/gutjnl-2021-326874 · Cited by 188 · see citing works
Pathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity
Bansal, S., & Bansal, M. B. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17930 · Cited by 204 · see citing works
“89–91 FFAs are one of the agents able to activate UPR – this is reviewed elsewhere.”
BackgroundKoutoukidis, D. A., Koshiaris, C., Henry, J. A., Noreik, M., Morris, E., Manoharan, I., Tudor, K., Bodenham, E., Dunnigan, A., Jebb, S. A., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154455 · Cited by 186 · see citing works
Harrison, S. A., Browne, S., Suschak, J. J., Tomah, S., Gutierrez, J. A., Yang, J., Roberts, M. S., & Harris, M. S. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.07.006 · Cited by 187 · see citing works
Wang, S., Li, K., Pickholz, E., Dobie, R., Matchett, K. P., Henderson, N. C., Carrico, C., Driver, I., Borch Jensen, M., Chen, L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add3949 · Cited by 176 · see citing works
“The whole-tissue fibrosis phenotype was described for its collagen content and structure (12 traits), the morphometric traits of the segmented collagen fibers (12), and fibrosis architecture traits (7).”
BackgroundLuci, C., Bourinet, M., Leclère, P. S., Anty, R., & Gual, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.597648 · Cited by 195 · see citing works
Management of non-alcoholic fatty liver disease
Petroni, M. L., Brodosi, L., Bugianesi, E., & Marchesini, G. (2021) · BMJ · doi:10.1136/bmj.m4747 · Cited by 181 · see citing works
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Yabut, J. M., & Drucker, D. J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 180 · see citing works
“Similarly, in a prospective study of individuals with severe obesity and biopsy-proven NASH, resolution of NASH without progression of hepatic fibrosis was reported in 81% of people examined after 1 year and 84% of subjects studied 5 years after bariatric surgery (93).”
Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease
Ramanathan, R., Ali, A. H., & Ibdah, J. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137280 · Cited by 179 · see citing works
“Bariatric surgery has been shown to improve steatosis, inflammation, and regress fibrosis in patients with obesity complicated by NASH [74].”
BackgroundRaverdy, V., Tavaglione, F., Chatelain, E., Lassailly, G., Vincentis, A. D., Gentilucci, U. V., Qadri, S. U., Caiazzo, R. J., Verkindt, H., Saponaro, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03283-1 · Cited by 189 · see citing works
“Liver histology was obtained at baseline through a percutaneous liver needle biopsy performed during surgery as previously described 42–44 .”
Self-citationEslam, M., Fan, J., Yu, M., Wong, V. W., Cua, I. H., Liu, C., Tanwandee, T., Gani, R. A., Seto, W., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 186 · see citing works
“Randomized controlled studies with bariatric surgery have demonstrated up to 3.6-fold higher efficacy in the resolution of biopsy-proven steatohepatitis without worsening of liver fibrosis compared to standard medical therapy [201]; these benefits can be sustained for up to 5 years [202].”
InfluentialSanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Abdelmalek, M. F., Ding, D., Han, L., Jia, C., Huss, R. S., Chung, C., et al. (2022) · Hepatology · doi:10.1002/hep.32204 · Cited by 171 · see citing works
ECM formation and degradation during fibrosis, repair, and regeneration
Mayorca‐Guiliani, A. E., Leeming, D. J., Henriksen, K., Mortensen, J. H., Nielsen, S. H., Anstee, Q. M., Sanyal, A. J., Karsdal, M. A., & Schuppan, D. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00063-4 · Cited by 172 · see citing works
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158 · see citing works
“Nevertheless, these interventions suggest that, like HCV and HBV, MASH fibrosis is reversible in noncir-rhotic liver, but unlike in HCV and HBV, there is no evidence yet that cirrhosis in MASH is reversible ( 254 ).”
BackgroundHealthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties
Allen, A. M., Lazarus, J. V., & Younossi, Z. M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.026 · Cited by 156 · see citing works
Fraile, J. M., Palliyil, S., Barelle, C. J., Porter, A. J., & Kovaleva, M. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s315724 · Cited by 152 · see citing works
Friend or foe? The elusive role of hepatic stellate cells in liver cancer
Cogliati, B., Yashaswini, C. N., Wang, S., Sia, D., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00821-z · Cited by 157 · see citing works
“In particular, a CAR T strategy to clear only senescent stellate cells reduces fibrosis in experimental CCl 4 or NASH mouse models 197 , but its effect on HCC development has not yet been assessed.”
BackgroundInfluentialBhattacharya, M., & Ramachandran, P. (2023) · Nature Immunology · doi:10.1038/s41590-023-01551-9 · Cited by 148 · see citing works
Harrison, S. A., Abdelmalek, M. F., Neff, G., Gunn, N., Guy, C. D., Alkhouri, N., Bashir, M. R., Freilich, B., Kohli, A., Khazanchi, A., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00017-6 · Cited by 148 · see citing works
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147 · see citing works
Yan, T., Luo, Y., Yan, N., Hamada, K., Zhao, N., Xia, Y., Wang, P., Zhao, C., Qi, D., Yang, S., et al. (2022) · Hepatology · doi:10.1002/hep.32538 · Cited by 125 · see citing works
“The risks of surgery procedures and side effects render bariatric surgery the last, but also almost the only, choice to treat morbid obesity and NASH.[4,5] When voluntary lifestyle and dietary strategies fail, alternative pharmacological therapeutics are urgently warranted.”
Background2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Kim, N. H., Seo, J. A., Kim, M. K., Lim, J. H., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0282 · Cited by 129 · see citing works
Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice
Duan, J., Wang, Z., Duan, R., Yang, C., Zhao, R., Feng, Q., Qin, Y., Jiang, J., Gu, S.-Y., Lv, K., et al. (2021) · Hepatology · doi:10.1002/hep.32148 · Cited by 120 · see citing works
“[2] Currently, lifestyle modification and bariatric surgery are the two most effective and evidence- based therapeutic options for early NASH.”
BackgroundInfluentialRustgi, V. K., Li, Y., Gupta, K., Minacapelli, C. D., Bhurwal, A., Catalano, C., & Elsaid, M. I. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.03.021 · Cited by 125 · see citing works
Song, Y., Guo, W., Li, Z., Guo, D. L., Zhao, L., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1058779 · Cited by 118 · see citing works
“According to a prospective 5-year follow-up of obesity patients with NASH by Lassailly et al, the positive effects of bariatric surgery on the resolution of NASH were long-lasting and resulted in a sustained decrease in fibrosis (28).”
BackgroundLoomba, R. S., Bédossa, P., Grimmer, K., Kemble, G. W., Martins, E. B., McCulloch, W. F., O’Farrell, M., Tsai, W.-W., Cobiella, J., Lawitz, E., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00246-2 · Cited by 121 · see citing works
Horn, D. B., Almandoz, J. P., & Look, M. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2051366 · Cited by 114 · see citing works
“4 kg/m(2)) was associated with long-term NASH resolution, with 84% of patients having NASH resolution without worsening in fibrosis starting at 1 year after surgery and persisting at 5 years [107].”
BackgroundEskridge, W., Cryer, D. R. H., Schattenberg, J. M., Gastaldelli, A., Malhi, H., Allen, A. M., Noureddin, M., & Sanyal, A. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196216 · Cited by 116 · see citing works
Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction
Salah, H. M., Pandey, A., Soloveva, A. E., Abdelmalek, M. F., Diehl, A. M., Moylan, C. A., Wegermann, K., Rao, V. N., Hernandez, A. F., Tedford, R. J., et al. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.07.010 · Cited by 106 · see citing works
“In a prospective study with biopsy-proven NASH, bariatric surgery resulted in resolution of NASH in 84% of patients at 1 year following surgery (120).”
BackgroundHarrison, S. A., Frías, J. P., Lucas, K. J., Reiss, G. M., Neff, G. W., Bollepalli, S., Su, Y., Chan, D. C., Tillman, E. J., Moulton, A. W., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.02.022 · Cited by 106 · see citing works
Roeb, E., Canbay, A. E., Tacke, F., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2283 · Cited by 102 · see citing works
Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies
Lee, Y. A., & Friedman, S. L. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13380 · Cited by 102 · see citing works
Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery
Pais, R., Aron‐Wisnewsky, J., Bedossa, P., Ponnaiah, M., Oppert, J., Siksik, J., Genser, L., Charlotte, F., Thabut, D., Clement, K., et al. (2022) · Hepatology · doi:10.1002/hep.32358 · Cited by 95 · see citing works
“This was suggested by Lassailly et al., albeit in a population with milder disease at baseline.”
BackgroundResultInfluentialTreatment of liver fibrosis: Past, current, and future
Zhang, C., Liu, S., & Yang, M. J. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i6.755 · Cited by 97 · see citing works
The Link between NAFLD and Metabolic Syndrome
Radu, F., Potcovaru, C.-G., Salmen, T., Filip, P. V., Pop, C. S., & Fierbinteanu-Braticevici, C. G. (2023) · Diagnostics · doi:10.3390/diagnostics13040614 · Cited by 87 · see citing works
“[34] reported long-term outcomes in a group of 180 patients with severe obesity and biopsy-confirmed NASH who underwent metabolic and bariatric surgery (MBS).”
Diabetes and cirrhosis: Current concepts on diagnosis and management
Castéra, L., & Cusi, K. J. (2023) · Hepatology · doi:10.1097/hep.0000000000000263 · Cited by 87 · see citing works
“1 year[136] and 5 years of follow-up.[137] Survival benefit with bariatric surgery has been demonstrated in general patient populations, although data for improved transplant-free survival in cirrhosis are lacking.”
BackgroundRomeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 91 · see citing works
“222 In a retrospective study, surgery was associated with a reduction of the 10-year adjusted risk of incident major adverse liver and cardiovascular outcomes of 12.4% and 13.9%, respectively.”
InfluentialSelf-citationNASH drug treatment development: challenges and lessons
Tilg, H., Byrne, C. D., & Targher, G. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00159-0 · Cited by 81 · see citing works
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84 · see citing works
“The reduction of fibrosis is progressive, beginning during the first year and continuing through 5 years [4,127].”
Bariatric surgery improves nonalcoholic fatty liver disease: systematic review and meta-analysis
Zhou, H., Luo, P., Li, P., wang, G., Yi, X., Fu, Z., Sun, X., Cui, B., Zhu, L., & Zhu, S. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06011-1 · Cited by 79 · see citing works
Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease
Yin, X., Guo, X., Liu, Z., & Wang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032844 · Cited by 78 · see citing works
Harrison, S. A., Manghi, F. P., Smith, W. B., Alpenidze, D., Aizenberg, D., Klarenbeek, N., Chen, C.-Y., Zuckerman, E., Ravussin, E., Charatcharoenwitthaya, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01861-9 · Cited by 75 · see citing works
Fianchi, F., Liguori, A., Gasbarrini, A., Grieco, A., & Miele, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126485 · Cited by 75 · see citing works
“, 2015 [178,179] 180 morbidly obese patients with biopsy-proven NASH Bariatric surgery (gastric banding; gastric bypass; Rouxen-Y-Gastric-bypass; sleeve gastrectomy) Prospective study 3 Bariatric surgery induced the disappearance of NASH from nearly 85% of patients and reduced the pathologic features of the disease af…”
BackgroundYan, M., Cui, Y., & Xiang, Q. (2025) · Theranostics · doi:10.7150/thno.106597 · Cited by 76 · see citing works
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Brennan, P. N., Elsharkawy, A. M., Kendall, T. J., Loomba, R., Mann, D. A., & Fallowfield, J. A. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00796-x · Cited by 68 · see citing works
Mejía-Guzmán, J. E., Belmont-Hernández, R. A., Chávez-Tapia, N. C., Uribe, M., & Nuño‐Lámbarri, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072959 · Cited by 72 · see citing works
“[ 132].”
Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation
Lonardo, A., Mantovani, A., Petta, S., Carraro, A., Byrne, C. D., & Targher, G. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00711-5 · Cited by 68 · see citing works
Prevention of cardiorenal complications in people with type 2 diabetes and obesity
Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.018 · Cited by 68 · see citing works
Bariatric Surgery and Osteoporosis
Paccou, J., Caiazzo, R. J., Lespessailles, É., & Cortet, B. (2021) · Calcified Tissue International · doi:10.1007/s00223-020-00798-w · Cited by 66 · see citing works
Self-citationIs there an ‘ideal’ diet for patients with NAFLD?
Pugliese, N., Torres, M. C. P., Petta, S., Valenti, L. V. C., Giannini, E. G., & Aghemo, A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13659 · Cited by 68 · see citing works
Bosch, J., Chung, C., Carrasco‐Zevallos, O. M., Harrison, S. A., Abdelmalek, M. F., Shiffman, M. L., Rockey, D. C., Shanis, Z., Juyal, D., Pokkalla, H., et al. (2021) · Hepatology · doi:10.1002/hep.32087 · Cited by 65 · see citing works
“9 53 (43, 63) 52 (38, 66) 68 (57, 78) 36 (25, 48)”
MethodInfluentialObesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease
Qadri, S. U., Ahlholm, N., Lønsmann, I., Pellegrini, P., Poikola, A., Luukkonen, P. K., Porthan, K., Juuti, A., Sammalkorpi, H. E., Penttilä, A. K., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab933 · Cited by 63 · see citing works
Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
Staufer, K., & Stauber, R. E. (2023) · Biomedicines · doi:10.3390/biomedicines11082108 · Cited by 63 · see citing works
“A French study with serial liver biopsies at the time of surgery, 1 year later, and 5 years later has demonstrated resolution of NASH without worsening of fibrosis at 5 years in 84% and improvement of fibrosis by ≥1 stage at 5 years in 70% of patients [103,104].”
BackgroundNdumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 87 · see citing works
Jirapinyo, P., Hadefi, A., Huberty, V., Sullivan, S. A., Thompson, C. C., Patai, Á. V., Pannala, R., Goelder, S. K., Kushnir, V. M., Barthet, M. A., et al. (2024) · Endoscopy · doi:10.1055/a-2292-2494 · Cited by 65 · see citing works
Self-citationTargeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy
Han, X., Ding, C., Sang, X., Peng, M., Yang, Q., Ning, Y., Lv, Q., Shan, Q., Hao, M., Wang, K.-L., et al. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107983 · Cited by 64 · see citing works
Armandi, A., & Bugianesi, E. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.01.005 · Cited by 60 · see citing works
“Morbidly obese patients undergoing bariatric surgery (sleeve gastrectomy and gastric bypass) were achieving MASH resolution in 85 % of cases after 1 year, and displayed progressive trends in fibrosis regression after 5 years [4].”
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90 · see citing works
Krishnan, A., Hadi, Y. B., Alqahtani, S. A., Woreta, T. A., Fang, W., Abunnaja, S., Szoka, N. L., Tabone, L. E., Thakkar, S. J., & Singh, S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.7188 · Cited by 54 · see citing works
Hwang, J., Hwang, H., Shin, H., Kim, B. H., Kang, S. H., Yoo, J., Choi, M. Y., Lee, D. E., Jun, D. W., & Cho, Y. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0384 · Cited by 54 · see citing works
Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet
Ganguly, S., Muench, G. A., Shang, L., Rosenthal, S. B., Rahman, G., Wang, R., Wang, Y., Kwon, H. C., Diomino, A. M., Kisseleva, T., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.05.010 · Cited by 50 · see citing works
Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis
Yang, Y., Xie, L. H., Zhang, N., Zhou, D., Liu, T., & Wu, J. H. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00860-3 · Cited by 53 · see citing works
“Bariatric surgery often leads to durable weight reduction, at the same time liver fat content is reduced, and hepatic fibrosis is improved [5]; nevertheless this procedure is not suggested for NASH patients as a practical guideline due to the surgical risk.”
BackgroundNestor, J. J., Parkes, D., Feigh, M., Suschak, J. J., & Harris, M. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-10577-2 · Cited by 53 · see citing works
Cariou, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14651 · Cited by 52 · see citing works
“2% and was completely resolved in 56%.(75) Regarding the procedure, it seems that both”
BackgroundBobowski, M., Boulet, C., Zummo, F. P., Dubois‐Chevalier, J., Gheeraert, C., Saleh, M. B., Strub, J., Farce, A., Ploton, M., Guille, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33063-9 · Cited by 47 · see citing works
Self-citationClapp, B. L., Portela, R. C., Sharma, I., Nakanishi, H., Marrero, K., Schauer, P. R., Halfdanarson, T. R., Dayyeh, B. A., Kendrick, M., & Ghanem, O. M. (2022) · British journal of surgery · doi:10.1093/bjs/znac343 · Cited by 51 · see citing works
- Authors
- Lassailly, G., Caiazzo, R., Ntandja-Wandji, L.-C., Gnemmi, V., Baud, G., Verkindt, H., Ningarhari, M., Louvet, A., Leteurtre, E., Raverdy, V., Dharancy, S., Pattou, F., & Mathurin, P.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Pattou, François
- Mathurin, Philippe
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 159
- Issue
- 4
- Pages
- 1290-1301.e5
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W3034346518
- Cited by
- 622
- References
- 27
- Citations by year
- 2026: 93 · 2025: 105 · 2024: 109 · 2023: 106 · 2022: 108 · 2021: 89 · 2020: 11
- FWCI
- 56.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Gastroenterology (acceptedVersion, other-oa)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc)
- HAL (submittedVersion)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, other-oa)
- Funders
- European Regional Development Fund
- Agence Nationale de la Recherche (ANR-10-LABX-46, ANR-16-RHUS-0006)
- Ministère des Affaires Sociales et de la Santé
- European Commission
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Keywords
- bariatric surgery, nonalcoholic steatohepatitis, liver fibrosis regression, obesity, long-term outcomes, weight loss, NASH resolution, liver biopsy histology, bridging fibrosis, metabolic surgery, liver cancer risk, liver transplantation risk
- MeSH terms
- Adult, Biopsy, Female, Follow-Up Studies, France, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Obesity, Morbid, Prospective Studies, Remission Induction, Time Factors, Weight Loss, Treatment Outcome, Bariatric Surgery, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
